Loading...
Loading...
Medical Disclaimer: This information is for educational purposes only and is not a substitute for professional medical advice.
Standardized Insect Venom Allergenic Extract [EPC]
Zinc Acetate Anhydrous is a copper absorption inhibitor primarily indicated for the maintenance treatment of patients with Wilson's disease. It works by inducing metallothionein in the intestinal mucosa to prevent systemic copper toxicity.
Name
Zinc Acetate Anhydrous
Raw Name
ZINC ACETATE ANHYDROUS
Category
Standardized Insect Venom Allergenic Extract [EPC]
Drug Count
12
Variant Count
15
Last Verified
February 17, 2026
About Zinc Acetate Anhydrous
Zinc Acetate Anhydrous is a copper absorption inhibitor primarily indicated for the maintenance treatment of patients with Wilson's disease. It works by inducing metallothionein in the intestinal mucosa to prevent systemic copper toxicity.
Detailed information about Zinc Acetate Anhydrous
This page is for informational purposes only and does not replace medical advice. Consult a qualified healthcare professional before using any medication containing Zinc Acetate Anhydrous.
Zinc Acetate Anhydrous is a potent pharmacological agent primarily utilized as a copper absorption inhibitor. It belongs to the therapeutic class of metal salts and is specifically categorized as an orphan drug for the maintenance treatment of Wilson's disease (an inherited disorder characterized by excessive copper accumulation). While the raw data may occasionally associate this ingredient with various allergenic extract classifications in specific regulatory databases, its primary clinical identity in human medicine is centered on trace element management and copper detoxification. The anhydrous form of zinc acetate is a white, crystalline powder that is highly soluble in water, making it an effective delivery vehicle for elemental zinc.
Approved by the U.S. Food and Drug Administration (FDA) in 1997 under the brand name Galzin, Zinc Acetate Anhydrous represented a significant advancement in the long-term management of Wilson's disease. Unlike chelating agents (such as penicillamine or trientine) which work by stripping copper from the blood and tissues and excreting it through the kidneys, zinc acetate works 'upstream' by preventing copper from entering the systemic circulation in the first place. It is essential to note that Zinc Acetate Anhydrous is specifically indicated for maintenance therapy in patients who have already been 'de-coppered' using chelating agents, rather than for the initial treatment of symptomatic patients with acute copper toxicity.
At the molecular level, Zinc Acetate Anhydrous functions through a unique mechanism of 'intestinal blockade.' When ingested, the zinc ions (Zn2+) released from the acetate salt stimulate the enterocytes (cells lining the small intestine) to produce a protein called metallothionein. Metallothionein is a cysteine-rich protein that has an exceptionally high affinity for copper—even higher than its affinity for zinc.
Once metallothionein is induced in the intestinal lining, it acts as a molecular sponge. As dietary copper passes through the intestinal lumen, it is captured by the metallothionein within the enterocytes. This copper is then 'trapped' inside the cell and prevented from crossing into the portal circulation. Because the cells of the intestinal lining are naturally sloughed off and excreted in the feces every few days, the trapped copper is eliminated from the body along with the cells. This process effectively creates a negative copper balance, or at least a neutral one, preventing the toxic accumulation of copper in the liver and brain that characterizes Wilson's disease.
Understanding the pharmacokinetics of Zinc Acetate Anhydrous is crucial for ensuring its clinical efficacy, as its absorption is highly sensitive to external factors.
The primary FDA-approved indication for Zinc Acetate Anhydrous is the maintenance treatment of patients with Wilson's disease who have been initially treated with chelating agents. By maintaining a state of negative copper balance, it prevents the recurrence of hepatic and neurological symptoms.
Off-label, zinc acetate is sometimes used in the treatment of the common cold (in lozenge form), although the anhydrous form discussed here is typically reserved for systemic copper management. It may also be used in specialized nutritional formulations for patients with severe zinc deficiency, though this is less common than the use of zinc sulfate or zinc gluconate for that purpose.
Zinc Acetate Anhydrous is most commonly available in the following forms:
> Important: Only your healthcare provider can determine if Zinc Acetate Anhydrous is right for your specific condition. Regular monitoring of 24-hour urinary copper and zinc levels is required to ensure the treatment is effective and safe.
For the maintenance treatment of Wilson's disease, the standard adult dosage of Zinc Acetate Anhydrous is 50 mg of elemental zinc taken three times daily (TID).
In some clinical scenarios, healthcare providers may adjust the dose based on the patient's copper levels and clinical response. Some patients may be maintained on 25 mg three times daily, while others may require more frequent dosing. The goal is to keep the 24-hour urinary copper excretion below 125 micrograms and to maintain non-ceruloplasmin-bound copper (free copper) within a safe range. It is vital that patients do not exceed the prescribed dose, as excessive zinc can lead to copper deficiency and related complications like anemia.
Zinc Acetate Anhydrous is approved for use in pediatric patients with Wilson's disease, typically starting at age 10 or older.
There are no specific dosage adjustment guidelines provided by the manufacturer for patients with renal impairment. However, because a portion of zinc is excreted renally, patients with significant kidney disease should be monitored closely for signs of zinc toxicity.
Since Wilson's disease itself causes hepatic impairment, Zinc Acetate Anhydrous is often used in patients with compromised liver function. No specific dose adjustment is usually required for hepatic impairment, but the underlying liver disease must be managed concurrently.
Clinical studies of Zinc Acetate Anhydrous did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function.
The timing of administration is the most critical factor in the success of Zinc Acetate Anhydrous therapy.
If you miss a dose of Zinc Acetate Anhydrous, take it as soon as you remember, provided it is still on an empty stomach. If it is almost time for your next dose, skip the missed dose and resume your regular schedule. Do not double the dose to catch up. Consistency is key in maintaining the 'intestinal blockade' of copper.
Acute overdose of Zinc Acetate Anhydrous can cause severe gastrointestinal distress, including nausea, vomiting, and abdominal pain. Long-term overdose can lead to severe copper deficiency, which may manifest as sideroblastic anemia (a condition where the bone marrow produces abnormal red blood cells) and leukopenia (low white blood cell count).
In case of an acute overdose, contact your local poison control center or seek emergency medical attention immediately. Treatment typically involves supportive care and, in severe cases, the use of chelating agents to remove excess zinc.
> Important: Follow your healthcare provider's dosing instructions exactly. Do not adjust your dose or stop taking the medication without medical guidance, as this could lead to a rapid and dangerous accumulation of copper.
The most frequently reported side effects of Zinc Acetate Anhydrous are gastrointestinal in nature. These occur because zinc can act as a direct irritant to the gastric mucosa (stomach lining).
> Warning: Stop taking Zinc Acetate Anhydrous and call your doctor immediately if you experience any of these serious symptoms:
The primary concern with long-term Zinc Acetate Anhydrous use is the potential for inducing 'over-correction' of copper levels. While the goal is to prevent copper toxicity, the body still requires trace amounts of copper for vital functions. Prolonged, excessive zinc intake can lead to profound copper depletion, resulting in permanent neurological damage or bone marrow suppression. Regular blood work and 24-hour urine collections are mandatory for patients on lifelong therapy to ensure they remain in the 'Goldilocks zone'—neither too much nor too little copper.
Additionally, long-term zinc supplementation can interfere with the absorption of other essential minerals, such as iron and calcium, potentially leading to secondary deficiencies if the diet is not properly balanced.
There are currently no FDA black box warnings for Zinc Acetate Anhydrous. However, the FDA-approved labeling emphasizes that it is not recommended for the initial treatment of symptomatic Wilson's disease patients because of the slow onset of action associated with the induction of metallothionein.
Report any unusual symptoms or changes in your health to your healthcare provider immediately. Regular laboratory monitoring is the best way to prevent serious side effects.
Zinc Acetate Anhydrous is a specialized medication that requires strict adherence to dosing protocols and frequent medical supervision. It is not a general-purpose zinc supplement and should only be used by patients with a confirmed diagnosis of Wilson's disease or other conditions specifically identified by a specialist. The most critical safety point is that Zinc Acetate Anhydrous is maintenance therapy, not a rescue medication for acute copper poisoning.
No FDA black box warnings for Zinc Acetate Anhydrous.
Patients taking Zinc Acetate Anhydrous must undergo regular laboratory testing. This typically includes:
Zinc Acetate Anhydrous does not typically cause drowsiness or cognitive impairment. However, patients with Wilson's disease may have underlying neurological symptoms that affect their ability to drive. If the medication causes severe nausea or headaches, patients should wait until these symptoms subside before operating heavy machinery.
Alcohol should be avoided or strictly limited. Alcohol can exacerbate the liver damage associated with Wilson's disease and may increase the risk of gastric irritation when combined with zinc acetate. Talk to your doctor about your alcohol consumption habits.
Zinc Acetate Anhydrous is usually a lifelong medication. Stopping the medication suddenly can lead to a rapid rise in free copper levels, which can cause a life-threatening 'copper storm' or acute liver failure. Never stop taking this medication without a direct order from your hepatologist or neurologist.
> Important: Discuss all your medical conditions, especially any history of stomach ulcers or kidney disease, with your healthcare provider before starting Zinc Acetate Anhydrous.
While there are few absolute contraindications, Zinc Acetate Anhydrous should never be taken at the same time as other oral medications that bind to metals.
Food is the most significant 'interactor' with Zinc Acetate Anhydrous.
> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking. Even 'natural' products can contain minerals that interfere with your treatment.
Zinc Acetate Anhydrous is absolutely contraindicated in the following individuals:
Conditions requiring careful risk-benefit analysis include:
There is no known cross-sensitivity between zinc acetate and other classes of drugs. However, patients who have had adverse reactions to other zinc salts (such as zinc sulfate or zinc gluconate) are likely to experience similar gastrointestinal side effects with zinc acetate, as the irritant effect is primarily due to the zinc ion itself.
> Important: Your healthcare provider will evaluate your complete medical history, including any history of digestive issues or blood disorders, before prescribing Zinc Acetate Anhydrous.
FDA Pregnancy Category A (in the context of Wilson's Disease). Zinc Acetate Anhydrous is one of the few medications where the benefit of maintaining treatment during pregnancy significantly outweighs the risks. Untreated Wilson's disease is highly dangerous for both the mother and the fetus, often leading to miscarriage or severe hepatic complications.
Zinc is naturally excreted in human breast milk. While zinc is an essential nutrient for infants, the high doses taken by mothers for Wilson's disease could theoretically affect the infant's mineral balance. However, limited data suggest that breastfeeding while taking Zinc Acetate Anhydrous is generally safe. The infant should be monitored by a pediatrician for normal growth and development.
Zinc Acetate Anhydrous is approved for the maintenance treatment of Wilson's disease in children, typically those aged 10 and older. In younger children, the medication is used off-label. The primary concern in pediatric populations is ensuring that the zinc does not cause a secondary copper deficiency that could interfere with normal growth and neurological development. Growth velocity and blood counts should be monitored regularly in children on long-term therapy.
Elderly patients may be more susceptible to the gastrointestinal side effects of Zinc Acetate Anhydrous. Additionally, because renal function often declines with age, the risk of zinc accumulation is higher. Geriatric patients often take multiple medications (polypharmacy), increasing the risk of drug-drug interactions with zinc. Doses should be started at the lower end of the adult range.
In patients with mild to moderate renal impairment, Zinc Acetate Anhydrous can usually be used with standard monitoring. In severe renal impairment (GFR < 30 mL/min), the frequency of monitoring for zinc toxicity and copper deficiency should be increased. Zinc is not significantly removed by hemodialysis.
No specific dose adjustments are required for patients with hepatic impairment, as the liver is not the primary route of zinc elimination. However, since these patients already have compromised liver function due to Wilson's disease, any sign of worsening liver enzymes should be carefully evaluated to distinguish between disease progression and drug-related issues.
> Important: Special populations, particularly pregnant women and children, require individualized medical assessment and frequent laboratory follow-ups.
Zinc Acetate Anhydrous acts as a 'pharmacological inducer' of endogenous proteins. Specifically, it targets the enterocytes of the duodenum and jejunum. Upon ingestion, zinc ions enter these cells and activate the transcription of the gene for metallothionein.
Metallothionein is a low-molecular-weight, metal-binding protein. It contains numerous cysteine residues that allow it to bind up to seven divalent metal atoms per molecule. While it binds zinc, it has a much higher affinity for copper. By increasing the concentration of metallothionein in the intestinal wall, Zinc Acetate Anhydrous ensures that dietary copper is sequestered within the enterocyte. This prevents the copper from being transported into the blood by the ATP7A protein. When the enterocytes are shed (every 3-4 days), the bound copper is excreted in the feces.
The pharmacodynamic effect of Zinc Acetate Anhydrous is not immediate. It requires several days of consistent dosing to induce sufficient levels of metallothionein to begin effectively blocking copper. The maximum effect on copper balance is usually seen after 2-3 weeks of continuous therapy. The duration of effect lasts as long as the medication is taken; however, once discontinued, the 'blockade' disappears within days as new enterocytes (without induced metallothionein) replace the old ones.
| Parameter | Value |
|---|---|
| Bioavailability | 20% - 50% (Highly dependent on food) |
| Protein Binding | 60% - 70% (Primarily to Albumin) |
| Half-life | Not applicable (Elemental mineral) |
| Tmax | 2 hours |
| Metabolism | None (Incorporated into proteins/enzymes) |
| Excretion | Fecal (80%), Renal (10-20%) |
Zinc Acetate Anhydrous is classified as a Copper Absorption Inhibitor and a Metal Salt. Within the context of Wilson's disease, it is considered an 'Orphan Drug.' It is distinct from chelating agents like trientine or penicillamine, which are 'Copper Eliminators.'
Medications containing this ingredient
Common questions about Zinc Acetate Anhydrous
Zinc Acetate Anhydrous is primarily used for the maintenance treatment of Wilson's disease, a rare genetic disorder where copper builds up to toxic levels in the body. It works by preventing the intestines from absorbing copper from food, which helps maintain a safe copper balance after initial treatment with other medications. It is not intended for the initial treatment of patients who already have severe symptoms of copper poisoning. Instead, it is a lifelong therapy used to prevent symptoms from returning. Your doctor may also use it in specific cases of zinc deficiency, though this is less common.
The most common side effects are gastrointestinal, including stomach ache, nausea, and a burning sensation in the upper abdomen. These symptoms occur because zinc can irritate the stomach lining, especially when taken on an empty stomach as required. Some patients may also experience a metallic taste in their mouth or mild diarrhea. In most cases, these side effects are most prominent during the first few weeks of treatment and may lessen over time. If the stomach pain is severe or persistent, you should contact your healthcare provider to rule out gastric erosions.
It is generally advised to avoid or strictly limit alcohol consumption while taking Zinc Acetate Anhydrous. Alcohol can irritate the stomach lining, which may worsen the gastric side effects of the medication. More importantly, Wilson's disease primarily affects the liver, and alcohol consumption can cause additional liver damage, complicating your condition. Combining alcohol with a condition that already stresses the liver is medically discouraged. Always discuss your lifestyle habits with your specialist to ensure the best outcome for your liver health.
Yes, Zinc Acetate Anhydrous is generally considered safe and is often the preferred treatment for Wilson's disease during pregnancy. It is classified as Pregnancy Category A in this context because the risks of untreated Wilson's disease to both the mother and baby are much higher than the risks of the medication. Studies have shown that women taking zinc acetate have had successful pregnancies with healthy babies. However, your doctor will monitor your copper and zinc levels very closely throughout each trimester. Dose adjustments are sometimes made in the final months of pregnancy to ensure the baby gets enough copper for its own development.
Zinc Acetate Anhydrous does not work immediately; it takes time to build up its effect in the body. It works by stimulating the production of a protein called metallothionein in your intestinal cells, a process that usually takes about two to three weeks of consistent dosing to reach full effectiveness. Because of this delay, it is not used for the initial 'emergency' phase of Wilson's disease treatment. You will likely be started on a faster-acting chelating agent first. Once your copper levels are under control, you will transition to zinc for long-term maintenance.
No, you should never stop taking Zinc Acetate Anhydrous suddenly unless specifically directed by your doctor. Wilson's disease is a lifelong condition, and the medication is what keeps your copper levels from becoming toxic. If you stop the medication, your body will immediately begin absorbing copper from your diet again, which can lead to a rapid and dangerous accumulation in your liver and brain. This can cause acute liver failure or severe neurological damage. If you are having trouble with side effects, talk to your doctor about adjusting the dose rather than stopping it.
If you miss a dose, take it as soon as you remember, but only if you are still on an empty stomach (1 hour before or 2 hours after a meal). If it is almost time for your next scheduled dose, skip the missed dose entirely and continue with your regular schedule. Do not take two doses at once to make up for the one you missed. The medication works best when taken at evenly spaced intervals throughout the day. If you find yourself frequently forgetting doses, talk to your pharmacist about using a pill organizer or a reminder app.
Weight gain is not a recognized or common side effect of Zinc Acetate Anhydrous. The medication primarily affects mineral absorption in the gut and does not have a direct impact on metabolism or appetite in a way that typically leads to weight changes. If you experience significant weight gain while taking this medication, it may be due to other factors, such as changes in your underlying liver condition or other medications you may be taking. You should discuss any unexpected weight changes with your healthcare provider to determine the cause.
Zinc Acetate Anhydrous has several significant drug interactions, so you must be careful. It can bind to other drugs in the stomach, such as certain antibiotics (quinolones and tetracyclines) and other minerals like iron or calcium, preventing them from being absorbed. It also interacts with chelating agents used for Wilson's disease, so they must be taken at different times. Always provide your doctor with a full list of all prescriptions, over-the-counter drugs, and herbal supplements you use. Most interactions can be managed by carefully timing when you take each medication.
Zinc Acetate is available as a prescription medication (brand name Galzin) and is also found in various over-the-counter zinc supplements. However, for the treatment of Wilson's disease, it is crucial to use the specific formulation and dosage prescribed by your doctor. OTC supplements are not regulated as strictly as prescription drugs and may not provide the precise amount of elemental zinc needed for medical maintenance. Generic versions of prescription zinc acetate capsules may be available in some regions, but you should always consult your pharmacist to ensure you are receiving the correct medical-grade product.